Large gap with delayed quotes
Analysis date: 18.09.2026
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 26.06.2026.
Quality
Strong
Strong
Three stars since 11.08.2026.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 07.07.2026 at a price of 112.05.
Evaluation
Overvalued
Overvalued
Based on its growth potential and our own criteria, we believe the share price is currently moderately overvalued.
MT Tech Trend
Positive
Positive
The dividend-adjusted forty day technical trend is positive since 08.05.2026.
4wk Rel Perf
26.65%
26.65%
The four-week dividend-adjusted overperformance versus SP500 is 26.65%.
Risk
Middle
Middle
The stock has been on the moderate-sensitivity level since 26.06.2026.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -0.33%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 2.89%.
Mkt Cap in $bn
16.01
16.01
With a market capitalization >$8bn, REVVITY is considered a large-cap stock.
G/PE Ratio
0.77
0.77
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) below 0.9 indicates that investors must pay a premium for the estimated growth potential:
LT P/E
21.95
21.95
The estimated PE is for the year 2028.
LT Growth
16.66%
16.66%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
16
16
Over the last seven weeks, an average of 16 analysts provided earnings per share estimates.
Dividend Yield
0.20%
0.20%
The twelve month estimated dividend yield represents 4.28% of earnings forecasts.
Beta
115
115
For 1% of index variation, the stock varies on average by 1.15%.
Correlation
0.35
0.35
Stock movements are strongly independent of index variations.
Value at Risk
34.43
34.43
The value at risk is estimated at USD 34.43. The risk is therefore 24.00%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
31.03.2004
31.03.2004